BackBlossomHill Therapeutics Overview

BlossomHill Therapeutics Long Term Debt

Track BlossomHill Therapeutics's long-term debt ($22M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$22.22M

Peer trimmed avg / median

Loading

BlossomHill Therapeutics Long Term Debt History

Loading

BlossomHill Therapeutics vs. peers: Long Term Debt Comparison

Loading

BlossomHill Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BlossomHill Therapeutics (BLSM) FAQ

As of the most recent data (June 2026), BLSM shows a long-term debt of $22M. Scroll down for historical charts and peer comparison views.

Tracking BLSM's long-term debt over time shows whether BlossomHill Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $22M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has BlossomHill Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $22M) with ownership activity and broader fundamentals.

BlossomHill Therapeutics's long-term debt is $22M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.